- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03986320
Bewertung der Wirksamkeit und Sicherheit von Keeogo™ Dermoskeleton bei Patienten mit eingeschränkter Mobilität aufgrund eines Schlaganfalls
Eine standortübergreifende, interventionelle, vergleichende, einarmige Studie zur Bewertung der Sicherheit und Wirksamkeit von Keeogo™ Dermoskeleton bei Patienten mit Hemiparese aufgrund eines ischämischen oder hämorrhagischen Schlaganfalls.
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Stroke affects thousands of individuals annually, leading to considerable physical impairment and functional disability. Gait is one of the most important activities of daily living affected in this patient population. Recent technological developments in passively powered dermoskeleton can create powerful adjunctive tools for rehabilitation and potentially accelerate functional recovery. Here, the investigators present the development and evaluation of a lower limb dermoskeleton, namely Keeogo™ (B-Temia), for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M6A 2E1
- Assistive Technology Clinic (ATC)
-
-
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Shirley Ryan Ability Lab (SRA)
-
-
New Jersey
-
West Orange, New Jersey, Vereinigte Staaten, 07052
- Human Performance and Engineering Research (HPER)
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10468
- James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
To be eligible to participate in this study, an individual must meet all of the following criteria:
-
Provide signed and dated informed consent form;
-
Willing to comply with all study procedures and be available for the duration of the study [2-3 days per week, 3-5 consecutive weeks];
-
Adults 18 years of age and older;
-
Confirmed Cerebrovascular Accident (CVA) with hemiparesis;
-
Stable stroke (≥ 6 months post-incident)
-
Sufficient cognition to follow simple instructions and understand the content and purpose of the study (MMSE > 20);
-
Capable of standing and walking independently for an extended period of time (MMT
- 3 hip flexors and extensors, and ≥ 2 knee flexors and extensors with BBS ≥ 45);
-
Presence of any gait deficit, as defined by one or more of the following clinical observations:
- Hip hike
- Hip circumduction
- Knee spasticity (MAS 2 to 3) as per Modified Ashworth Scale (MAS)
- Mid-foot striking (aka 'flat foot landing')
- Poor foot clearance (toe/foot drop or foot drag)
- Narrow steps (< 1 shoe-width or < 8 cm)
-
Manual Muscle Test (MMT) of 4/5 for the unaffected upper extremity;
-
Able to sit on a bench for more than 5 minutes;
-
Is physically and mentally compatible with device to demonstrate ability to safely activate the Keeogo™ user interface;
-
Able to understand and follow instructions with assistance if needed.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Legally blind
- Pregnant, lactating, or postpartum sacroiliac joint recovery is ongoing (recent childbirth, not yet cleared for vigorous exercise)
- Skin condition that contraindicates use of orthotics or support braces
- Recent (<6 mo) lower-body hospitalizations or active treatments due to a joint, muscle, bone, nerve or vascular injury or condition
- Scheduled for major surgery within next 4 months
- Lower-extremity amputation above or below the knee
- Have uncontrolled hypertension
- Recent (<1 year) heart attack
- Have uncontrolled diabetes
- Diagnosed with other health condition(s) that affect mobility and balance; chronic obstructive pulmonary disease; peripheral arterial disease; vestibular disorders; cerebellar disease; cerebral palsy; muscular dystrophy spinal cord injury; other brain injury aside from the reported CVA;
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Keeogo™ Dermoskeleton
Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves. |
This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of device-related adverse events [Safety]
Zeitfenster: Duration of study participation for each subject, estimated 3-5 weeks
|
Safety will be evaluated on the basis of the number of device-related serious adverse events reported for subjects during their participation in the study. |
Duration of study participation for each subject, estimated 3-5 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of device malfunctions during study procedures [Device Reliability]
Zeitfenster: Duration of study completion for each site, estimated 3-5 weeks
|
Device reliability will be evaluated on the basis of the number of device malfunctions reported by research study staff for the duration of study procedures at each study site. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Incidence of injury to Physical Therapist (PT) caused by device [PT safety]
Zeitfenster: Duration of study completion for each site, estimated 3-5 weeks
|
PT safety will be evaluated on the basis of the number of serious device-related injuries reported by study physical therapists for the duration of study procedures at each study site. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Device, Effectiveness
Zeitfenster: Duration of study participation for each subject, estimated 3-5 weeks
|
Clinician and Patient Reported Outcomes (surveys) will be used to assess the effectiveness of the device in assisting gait. The surveys will rate subject performance in walking based on clinician observed deviations and subject perception of mobility limitation due to the stroke.
|
Duration of study participation for each subject, estimated 3-5 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
30-Second Chair Stand Test
Zeitfenster: Duration of study completion for each site, estimated 3-5 weeks
|
Subjects sit in the middle of chair and place hands on opposite shoulder crossed at wrists. Keeping feet flat on floor, back straight, arms against chest, subjects rise to full standing position when told "go" followed by sit down, the start position. This movement is repeated for as many times as possible for 30 seconds. Additionally, the test is repeated for a total of 5 cycles with short rest (≤ 90 seconds) between sets. Patient and Clinician reported outcomes are assessed for this measure via a sit-to-stand-to-sit question on the survey given for the secondary effectiveness endpoint. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Timed Stair Test
Zeitfenster: Duration of study completion for each site, estimated 3-5 weeks
|
Subjects start with both feet on the bottom landing then ascend and descend a set number of stairs as quickly as possible in a safe manner using a rail only if needed. Time is recorded from ascent through descent. Patient and Clinician reported outcomes are assessed for this measure via a stair ascent/descent question on the survey given for the secondary effectiveness endpoint. |
Duration of study completion for each site, estimated 3-5 weeks
|
|
Patient and Clinician Reported Outcomes (surveys)
Zeitfenster: Duration of study completion for each site, estimated 3-5 weeks
|
Questionnaires provide patient and clinician-centric view of treatment of gait deficit. |
Duration of study completion for each site, estimated 3-5 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Arun Jayaraman, PT, PhD., Shirley Ryan Ability Lab (SRA)
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Buesing C, Fisch G, O'Donnell M, Shahidi I, Thomas L, Mummidisetty CK, Williams KJ, Takahashi H, Rymer WZ, Jayaraman A. Effects of a wearable exoskeleton stride management assist system (SMA(R)) on spatiotemporal gait characteristics in individuals after stroke: a randomized controlled trial. J Neuroeng Rehabil. 2015 Aug 20;12:69. doi: 10.1186/s12984-015-0062-0.
- Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: Final Data for 2016. Natl Vital Stat Rep. 2018 Jul;67(5):1-76.
- He Y, Eguren D, Luu TP, Contreras-Vidal JL. Risk management and regulations for lower limb medical exoskeletons: a review. Med Devices (Auckl). 2017 May 9;10:89-107. doi: 10.2147/MDER.S107134. eCollection 2017.
- Lee SH, Lee HJ, Chang WH, Choi BO, Lee J, Kim J, Ryu GH, Kim YH. Gait performance and foot pressure distribution during wearable robot-assisted gait in elderly adults. J Neuroeng Rehabil. 2017 Nov 28;14(1):123. doi: 10.1186/s12984-017-0333-z.
- Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9.
Nützliche Links
- <p>Mapping Connections. An Understanding of Neurological Conditions in Canada. The National Population Health Study of Neurological Conditions.: Neurological Health Charities Canada. Government of Canada. Canadian Institutes of Health Research.</p>
- <p>Canada S. Canada at a Glance 2018. Population</p>
- <p>Medical Devices; Physical Medicine Devices; Classification of the Powered Exoskeleton A Rule by the Food and Drug Administration on 02/24/2015</p>
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Ischämischer Schlaganfall
- Hämorrhagischer Schlaganfall
- Streicheln
- Parese
Andere Studien-ID-Nummern
- KEOG-SE-002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .